Product Description
Aspherical IOL (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886904/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intraocular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SIOLvsAIOL | N/A |
Completed |
Cataract |
2016-06-01 |
|
| ChiCTR-ONRC-12002154 | N/A |
Completed |
Cataract |
2011-11-30 |